Why does lung cancer come back? new study hunts for genetic clues

NCT ID NCT06477055

Completed Knowledge-focused Sponsor: Hunan Province Tumor Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study is for people with early-stage lung cancer whose cancer returned after taking the drug osimertinib. Researchers will analyze tumor or blood samples to find gene changes linked to the recurrence. The goal is to better understand why some cancers come back, which could help develop smarter treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could reveal why some lung cancers return after osimertinib, pointing toward better treatments or prevention strategies for recurrence.
What could go wrong: This is an observational study with only 60 participants, so findings may not apply to all patients. It does not test a new treatment, so no direct benefit to participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Locations

Hunan Provincal Tumor Hospital

Changsha, Hunan, 410013, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.